HealthTree Foundation for T-Cell Prolymphocytic Leukemia, Isocitrate Dehydrogenase-2 (IDH2) Inhibitor Treatments and Medications
[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back TREATMENTS
Isocitrate Dehydrogenase-2 (IDH2) Inhibitor
Enasidenib is an oral, selective, mutant IDH2 inhibitor approved for IDH2-mutated (mIDH2) relapsed/refractory acute myeloid leukemia.
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest T-Cell Prolymphocytic Leukemia Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.

Education

News Articles My Journal University Expert Webinars Find a Specialist HealthTree Podcast

Community

Connect Moves All Events

Cure Hub

HealthTree Cure Hub Find Side Effects Solutions See Tracked Labs Connect Medical Records Twin Machine Clinical Trial Finder

Get Involved

Join a Regional Cure Team Create a fundraiser Tribute Donate Patient Surveys & Studies Connect Medical Records

About us

Our Story

Need Help?

Contact Us FAQ & Help Center 1-800-709-1113

Legal Info

Terms of Use Privacy Policy
Download our App
Download iOS App Download Android App

Charity Navigator https://www.guidestar.org/profile/45-5354811

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2025 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811